Advertisement
Advertisement

RGEN

RGEN logo

Repligen Corp

149.37
USD
Sponsored
-7.05
-4.51%
Jan 30, 16:00 UTC -5
Closed
exchange

Pre-Market

149.21

-0.16
-0.11%

RGEN Earnings Reports

Positive Surprise Ratio

RGEN beat 33 of 40 last estimates.

83%

Next Report

Date of Next Report
Feb 25, 2026
Estimate for Q4 25 (Revenue/ EPS)
$196.77M
/
$0.44
Implied change from Q3 25 (Revenue/ EPS)
+4.22%
/
-4.35%
Implied change from Q4 24 (Revenue/ EPS)
+17.44%
/
--

Repligen Corp earnings per share and revenue

On Oct 28, 2025, RGEN reported earnings of 0.46 USD per share (EPS) for Q3 25, beating the estimate of 0.42 USD, resulting in a 7.78% surprise. Revenue reached 188.81 million, compared to an expected 184.97 million, with a 2.08% difference. The market reacted with a -5.92% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 22 analysts forecast an EPS of 0.44 USD, with revenue projected to reach 196.77 million USD, implying an decrease of -4.35% EPS, and increase of 4.22% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
For Q3 2025, Repligen Corp reported EPS of $0.46, beating estimates by 7.78%, and revenue of $188.81M, 2.08% above expectations.
The stock price moved down -5.92%, changed from $161.10 before the earnings release to $151.57 the day after.
The next earning report is scheduled for Feb 25, 2026.
Based on 22 analysts, Repligen Corp is expected to report EPS of $0.44 and revenue of $196.77M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement